Approved for the application of a booster dose of the Comirnaty vaccine in children and adolescents

Anvisa authorized the last second-fair (12/05) to alter the dosage of the Comirnaty vaccine, a vaccine for Covid-19, from the Pfizer company. The change was requested in June/2022 and will result in the inclusion in the product package of recommendations for the application of a booster dose to the primary vaccination scheme in children from 5 years of age and adolescents.

The application of the booster dose (third dose) was not authorized for those over 18 years of age.

For authorization, Anvisa evaluated the clinical data sent by the company and concluded that the benefits of altering the dosage outweigh the risks in the application of the booster dose in age groups.

The vaccines against Covid-19 have shown, in general, the decay of two antibodies over time, justifying the periodic evaluation of the need to apply booster doses, with the objective of maintaining adequate levels of antibodies capable of neutralizing the causative virus. da doença

The Comirnaty vaccine for use in Brazil is registered with Anvisa since February 23, 2021, with indication for immunization of a wide age group, starting from 6 months of age.

It is recommended that all people keep their reinforcement doses in the day in order to improve protection against serious cases and deaths from Covid-19.